For UK pharmaceutical and life sciences leaders
Your NHS strategy is leaving a multi-billion-pound private market untouched
Private healthcare in the UK runs on different formularies, different relationships, and different access pathways. Applying your NHS approach here does not work, and most pharma teams know it.
Two minutes. Solva follows up with specific private market access options.
- Missed commercial opportunities and stagnant private market revenue streams
- Products with strong NHS uptake failing to gain traction in the private sector
- Lack of engagement with key private hospital groups and independent practitioners
- Inefficient resource allocation due to a 'one-size-fits-all' market access approach
- Inefficient sales and marketing efforts targeting the wrong stakeholders
- Suboptimal product positioning and messaging for private patients and providers
- Loss of potential revenue from a growing market segment
- Reduced return on investment for products with private market applicability
- Perception as an NHS-only provider, limiting broader market influence
- Missed opportunities to support patient choice and access to innovative treatments
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
The UK private healthcare market operates on different purchasing and prescribing dynamics to the NHS. Formularies, relationships, and access pathways are all different. Most pharma companies apply their NHS strategy to the private market and wonder why it doesn't work.
What is the cost of leaving it unaddressed?
The UK private healthcare market was valued at £12.4 billion in 2023, projected to exceed £13.8 billion by 2025 (Petauri, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.